Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906617 · ClinicalTrials.gov registry record · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
A Phase 4 study of Robotic Lung Surgery, sponsored by The Cooper Health System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT03906617: Recruiting Phase 4 study of Robotic Lung Surgery, sponsored by The Cooper Health System.
NCT03906617 is a Phase 4 study of Robotic Lung Surgery that is actively recruiting participants, run by The Cooper Health System. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03906617, a Phase 4 study of Robotic Lung Surgery, is actively recruiting participants, sponsored by The Cooper Health System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.
Primary Outcome
Visual Analogue Scale (VAS) pain score will be assessed for non-inferiority of bupivacaine/epinephrine +dexamethasone vs. liposomal bupivacaine. A non-inferiority margin of 2 points on the VAS scale will be considered non-inferior.
Conditions Studied
Interventions
- DRUG Intercostal nerve block and wound infiltration with liposomal bupivacaine
- DRUG Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
Study Locations (1)
New Jersey
- Cooper University Hospital - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2022-06-10 |
| Phase | Phase 4 |
What NCT03906617 shows while recruiting
NCT03906617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Robotic Lung Surgery appearing as the primary indexed condition, and to 2 interventions - of which Intercostal nerve block and wound infiltration with liposomal bupivacaine is the first listed.
NCT03906617 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03906617 about?
NCT03906617 is a clinical study titled "Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine". This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been ...
What is the current status of trial NCT03906617?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2019-04-10. Estimated completion is 2022-06-10.
What conditions does trial NCT03906617 study?
This clinical trial studies the following conditions: Robotic Lung Surgery.
What interventions are being tested in trial NCT03906617?
The interventions under investigation include: Intercostal nerve block and wound infiltration with liposomal bupivacaine (DRUG), Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03906617?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03906617 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03906617's enrollment target sits among peer trials
34 1520th of 2000 higher than 474 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
- NCT04315233 · 34 participants · Phase 1
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI